The classification and diagnostic algorithm for primary lymphatic dysplasia: An update from 2010 to include molecular findings

Clinical Genetics

Volumn 84, Issue 4, 2013, Pages 303-314

  Connell, Fc ^a   Gordon, K ^b   Brice, G ^b   Keeley, V ^c   Jeffery, S ^b   Mortimer, Ps ^b   Mansour, S ^b   Ostergaard, P ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

FLT4 VEGFR3; FOXC2; GATA2; Generalized lymphatic dysplasia; GJC2; KIF11; Lymphoedema; Phenotyping; VEGFC

Indexed keywords

AKT1 GENE; AKT2 GENE; AKT3 GENE; ALGORITHM; ANGIOOSTEOHYPERTROPHY SYNDROME; CCBE1 GENE; CLASSIFICATION ALGORITHM; CLOVES SYNDROME; CONGENITAL MULTISEGMENTAL LYMPHEDEMA; DIAGNOSTIC ALGORITHM; DISEASE CLASSIFICATION; DYSPLASIA; EMBERGER SYNDROME; FLT4 GENE; FOUR LIMB LYMPHEDEMA; FOXC2 GENE; GATA2 GENE; GENE; GENE MUTATION; GJA1 GENE; GJC2 GENE; HENNEKAM SYNDROME; HUMAN; KIF11 GENE; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; LYMPHEDEMA DISTICHIASIS; LYMPHOSCINTIGRAPHY; MCLMR SYNDROME; MEIGE DISEASE; MICROCEPHALY CHORIORETINOPATHY LYMPHEDEMA MENTAL RETARDATION; MILROY DISEASE; MILROY LIKE LYMPHEDEMA; MOLECULAR DIAGNOSIS; MTOR GENE; MULTIPLE CANCER; NONHUMAN; NOONAN SYNDROME; OCULODENTODIGITAL SYNDROME; PIK3CA GENE; PIK3R2 GENE; PRADER WILLI SYNDROME; PRIMARY LYMPHATIC DYSPLASIA; PRIORITY JOURNAL; REVIEW; TURNER SYNDROME; VEGFC GENE; VEGFR3 GENE; WILD SYNDROME;

FLT4/VEGFR3; FOXC2; GATA2; GENERALIZED LYMPHATIC DYSPLASIA; GJC2; KIF11; LYMPHOEDEMA; PHENOTYPING; VEGFC;

ALGORITHMS; HUMANS; LYMPHEDEMA;

EID: 84883774229     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12173     Document Type: Review

References (79)

1. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006: 155: 947-950.
2. Durr HR, Pellengahr C, Nerlich A et al. Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa 2004: 33: 42-45.
3. Alitalo K. The lymphatic vasculature in disease. Nat Med 2011: 17: 1371-1380.
4. Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012: 30: 3726-3733.
5. Bull RH, Gane JN, Evans JEC, Joseph AEA, Mortimer PS. Abnormal lymph-drainage in patients with chronic venous leg ulcers. J Am Acad Dermatol 1993: 28: 585-590.
6. Chakraborty S, Gurusamy M, Zawieja DC, Muthuchamy M. Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis. Microcirculation 2012 Epub ahead of print. DOI: 10.1111/micc.12031.
7. Stoberl C, Partsch H. Erysipelas and lymphedema - egg or hen. Zeitschrift Fur Hautkrankheiten H&G 1987: 62: 56-62.
8. Dale RF. The inheritance of primary lymphoedema. J Med Genet 1985: 22: 274-278.
9. Moffatt CJ, Franks PJ, Doherty DC et al. Lymphoedema: an underestimated health problem. QJM 2003: 96: 731-738.
10. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Concensus Document of the International Society of Lymphology. Lymphology 2009: 42: 51-60.
11. Stemmer R. A clinical sign for the early and differential diagnosis of lymph edema. Vasa 1976: 5: 261-262.
12. Lee B, Andrade M, Bergan J et al. Diagnosis and treatment of primary lymphedema. Consensus Document of the International Union of Phlebology (IUP)-2009 (vol 29, pg 454, 2010). Int Angiol 2010: 29: 454-570.
13. Framework L. Best practice for the management of lymphoedema. International Consensus: MEP Ltd, 2006.
14. Brorson H. From lymph to fat: liposuction as a treatment for complete reduction of lymphedema. Int J Low Extrem Wounds 2012: 11: 10-19.
15. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010: 140: 460-476.
16. Norrmen C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation 2011: 123: 1335-1351.
17. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol 2011: 193: 607-618.
18. Ferrell RE, Levinson KL, Esman JH et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 1998: 7: 2073-2078.
19. Evans AL, Brice G, Sotirova V et al. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet 1999: 64: 547-555.
20. Karkkainen MJ, Ferrell RE, Lawrence EC et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000: 25: 153-159.
21. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000: 67: 295-301.
22. Mangion J, Rahman N, Mansour S et al. A gene for lymphedema-distichiasis maps to 16q24.3. Am J Hum Genet 1999: 65: 427-432.
23. Fang JM, Dagenais SL, Erickson RP et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000: 67: 1382-1388.
24. Brice G, Mansour S, Bell R et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002: 39: 478-483.
25. Allen E. Lymphoedema of the extremities. Classification, etiology and differential diagnosis: a study of three hundred cases. Arch Intern Med 1934: 54: 606-624.
26. Kinmonth JB, Taylor GW, Tracy GD, Marsh JD. Primary lymphoedema; clinical and lymphangiographic studies of a series of 107 patients in which the lower limbs were affected. Br J Surg 1957: 45: 1-9.
27. Connell F, Brice G, Jeffery S et al. A new classification system for primary lymphatic dysplasias based on phenotype. Clin Genet 2010: 77: 438-452.
28. Warsof SL, Nicolaides KH, Rodeck C. Immune and nonimmune hydrops. Clin Obstet Gynecol 1986: 29: 533-542.
29. Brice G, Ostergaard P, Jeffery S, Gordon K, Mansour S, Mortimer PS. A novel mutation in GJA1 causing oculodentodigital syndrome and primary lymphoedema in a three generation family. Clin Genet 2013. DOI: 10.1111/cge.12158
30. Hennekam RCM, Geerdink RA, Hamel BCJ et al. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental-retardation. Am J Med Genet 1989: 34: 593-600.
31. Leung AKC. Dominantly inherited syndrome of microcephaly and congenital lymphedema. Clin Genet 1985: 27: 611-612.
32. Opitz JM. On congenital lymphedema. Am J Med Genet 1986: 24: 127-129.
33. Jeffries GH, Chapman A, Sleisenger MH. Low-fat diet in intestinal lymphangiectasia. Its effect on albumin metabolism. N Engl J Med 1964: 270: 761-766.
34. Bellini C, Mazzella M, Arioni C et al. Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia. Am J Med Genet A 2003: 120A: 92-96.
35. Van Balkom IDC, Alders M, Allanson J et al. Lymphedema-lymphangiectasia-mental retardation (Hennekam) syndrome: a review. Am J Med Genet 2002: 112: 412-421.
36. Alders M, Hogan BM, Gjini E et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 2009: 41: 1272-1274.
37. Connell F, Kalidas K, Ostergaard P et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet 2010: 127: 231-241.
38. Hogan BM, Bos FL, Bussmann J et al. ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat Genet 2009: 41: 396-398.
39. Bos FL, Caunt M, Peterson-Maduro J et al. CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res 2011: 109: 486-491.
40. Connell FC, Kalidas K, Ostergaard P et al. CCBE1 mutations can cause a mild, atypical form of generalized lymphatic dysplasia but are not a common cause of non-immune hydrops fetalis. Clin Genet 2012: 81: 191-197.
41. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997: 13: 375-423.
42. Lee JH, My H, Silhavy JL et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012: 44: 941-945.
43. Kurek KC, Luks VL, Ayturk UM et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012: 90: 1108-1115.
44. Lindhurst MJ, Parker VER, Payne F et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 2012: 44: 928-933.
45. Riviere J-B, Mirzaa GM, O'Roak BJ et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012: 44: 934-940.
46. Lindhurst MJ, Parker VER, Payne F et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 2012: 44.
47. Biesecker L. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet 2006: 14: 1151-1157.
48. Lindhurst MJ, Sapp JC, Teer JK et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011: 365: 611-619.
49. Kreuter A, Hochdorfer B, Brockmeyer NH et al. A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia - WILD syndrome. Arch Dermatol 2008: 144: 366-372.
50. Milroy W. An undescribed variety of hereditary edema. NY Med J 1892: 56: 505-508.
51. Brice G, Child AH, Evans A et al. Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 2005: 42: 98-102.
52. Ghalamkarpour A, Morlot S, Raas-Rothschild A et al. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet 2006: 70: 330-335.
53. Gordon K, Spiden SL, Connell FC et al. FLT4/VEGFR3 and milroy disease: novel mutations, a review of published variants and database update. Hum Mutat 2013: 34: 23-31.
54. Karkkainen MJ, Saaristo A, Jussila L et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001: 98: 12677-12682.
55. Mellor RH, Hubert CE, Stanton AWB et al. Lymphatic dysfunction, not aplasia, underlies milroy disease. Microcirculation 2010: 17: 281-296.
56. Connell FC, Ostergaard P, Carver C et al. Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. Hum Genet 2009: 124: 625-631.
57. Kaipainen A, Korhonen J, Mustonen T et al. Expression of the fms-like tyrosine kinase-4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995: 92: 3566-3570.
58. Gordon K, Schulte D, Brice G et al. Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. Circ Res 2013: 112: 956-960.
59. Kuchler AM, Gjini E, Peterson-Maduro J et al. Development of the zebrafish lymphatic system requires VEGFC signaling. Curr Biol 2006: 16: 1244-1248.
60. Ostergaard P, Simpson MA, Mendola A et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 2012: 90: 356-362.
61. Kuhnt H IV. Ueber distichiasis (congenita) vera. Ophthalmologica 1899: 2: 46-57.
62. Brice G, Mansour S, Bell R et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002: 39: 478-483.
63. Bell R, Brice G, Child AH et al. Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum Genet 2001: 108: 546-551.
64. Norrmen C, Ivanov KI, Cheng J et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol 2009: 185: 439-457.
65. Petrova TV, Karpanen T, Norrmen C et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004: 10: 974-981.
66. Mellor RH, Brice G, Stanton AWB et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007: 115: 1912-1920.
67. Meige H. Dystrophie oedemateuse hereditaire. Presse Med 1898: 6: 341-343.
68. Rezaie T, Ghoroghchian R, Bell R et al. Primary non-syndromic lymphoedema (Meige disease) is not caused by mutations in FOXC2. Eur J Hum Genet 2008: 16: 300-304.
69. Emberger JM, Navarro M, Dejean M, Izarn P. Deaf mutism, lymphedema of the lawer limbs and hematological anomalies (acute-leukemia, cytopenia) with autosomal dominant transmission. J Genet Hum 1979: 27: 237-245.
70. Mansour S, Connell F, Steward C et al. Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am J Med Genet A 2010: 152A: 2287-2296.
71. Ostergaard P, Simpson MA, Connell FC et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011: 43: 929-931.
72. Khandekar M, Brandt W, Zhou Y et al. A Gata2 intronic enhancer confers its pan-endothelia-specific regulation. Development 2007: 134: 1703-1712.
73. Kazenwadel J, Secker GA, Liu YJ et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012: 119: 1283-1291.
74. Hahn CN, Chong C-E, Carmichael CL et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011: 43: U1012-U1130.
75. Hsu AP, Sampaio EP, Khan J et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011: 118: 2653-2655.
76. Dickinson RE, Griffin H, Bigley V et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011: 118: 2656-2658.
77. Ferrell RE, Baty CJ, Kimak MA et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet 2010: 86: 943-948.
78. Ostergaard P, Simpson MA, Brice G et al. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. J Med Genet 2011: 48: 251-255.
79. Orthmann-Murphy JL, Salsano E, Abrams CK et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain 2009: 132: 426-438.